NDK: A Potential Drug Target Or Biomarker (P39379)

Target Name: Nucleoside Diphosphate Kinase (NDK)

NCBI ID: P39379

Nucleoside Diphosphate Kinase (NDK)

Other Name(s): NME | NDK | NDP kinase | Histidine protein kinase NDK

NDK: A Potential Drug Target Or Biomarker

Nucleoside Diphosphate Kinase (NDK), also known as nonspecific subtype (NME), is an enzyme that plays a crucial role in the regulation of DNA replication and repair. The NDK is a key enzyme in the DNA replication process, as it helps to ensure that the new DNA strand is copied accurately.

The NDK is a protein that is composed of two subunits, named alpha and beta subunits. The alpha subunit is responsible for the transfer of the nucleoside diphosphate (NDP) to the 5' end of the newly synthesized DNA strand, while the beta subunit is responsible for removing the NDP from the 3' end of the newly synthesized DNA strand.

The NDK enzyme has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, cardiovascular disease, and neurodegenerative diseases.

One of the main reasons for the potential targeting of the NDK is its involvement in the regulation of DNA replication and repair. Many diseases are caused by disruptions in the regulation of DNA replication, which can lead to the accumulation of mutations and other genetic alterations. The NDK plays a key role in ensuring that the new DNA strand is accurately copied, which helps to prevent the accumulation of genetic alterations.

In addition, the NDK is also involved in the regulation of cell signaling pathways, which are important for many cellular processes, including cell growth, differentiation, and survival. The NDK has been shown to play a role in the regulation of cell signaling pathways, which suggests that it may be a useful target for the development of new drugs for a variety of diseases.

Another potential reason for the targeting of the NDK is its involvement in the regulation of DNA repair pathways. DNA repair is an important process that helps to ensure that the DNA is repaired after an error has been made. The NDK is involved in the regulation of DNA repair pathways, which suggests that it may be a useful target for the development of drugs that promote DNA repair and prevent the accumulation of genetic alterations.

The NDK is also a potential biomarker for a variety of diseases. The NDK is expressed in most tissues and cells, but its levels can vary depending on the specific tissue or cell type. This variation in the levels of the NDK can be used as a diagnostic tool for diseases that affect DNA replication and repair. For example, the NDK is often reduced in tissues or cells that are affected by cancer, cardiovascular disease, or neurodegenerative diseases.

In conclusion, the NDK is an enzyme that plays a crucial role in the regulation of DNA replication and repair. Its involvement in these processes makes it a potential drug target or biomarker for a variety of diseases. Further research is needed to fully understand the role of the NDK in the regulation of DNA replication and repair, as well as its potential as a drug target or biomarker.

Protein Name: Nucleoside Diphosphate Kinase (NDK) (nonspecified Subtype)

The "Nucleoside Diphosphate Kinase (NDK) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Nucleoside Diphosphate Kinase (NDK) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets